Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial

Journal article


Publication Details

Author(s): Schneeweiss A, Moebus V, Tesch H, Hanusch C, Denkert C, Luebbe K, Huober J, Klare P, Kuemmel S, Untch M, Kast K, Jackisch C, Thomalla J, Ingold-Heppner B, Blohmer JU, Rezai M, Frank M, Engels K, Rhiem K, Fasching P, Nekljudova V, Von Minckwitz G, Loibl S
Journal: European journal of cancer
Publication year: 2019
Volume: 106
Pages range: 181-192
ISSN: 0959-8049


Abstract

Background: GeparOcto compared efficacy and safety of two chemotherapy regimens in high-risk early breast cancer (BC): sequential treatment with intense dose-dense epirubicin, paclitaxel, and cyclophosphamide (iddEPC) and weekly treatment with paclitaxel plus non-pegylated liposomal doxorubicin (M, Myocet®) with additional carboplatin (PM(Cb)) in triple-negative BC (TNBC). Patients and methods: Patients with cT1c-cT4a-d and centrally assessed human epidermal growth factor receptor (HER)2-positive BC or TNBC were eligible, irrespective of nodal status, luminal B-like tumours only if pN+. Patients were randomised (stratified by BC subtype, Ki67, lymphocyte-predominant BC) to receive 18 weeks of E (150 mg/m
2
) followed by P (225 mg/m
2
) followed by C (2000 mg/m
2
), each q2w for 3 cycles or weekly P (80 mg/m
2
) plus M (20 mg/m
2
) plus, in TNBC, Cb (area under curve (AUC) 1.5). HER2-positive BC patients additionally received trastuzumab (6 [loading dose 8]mg/kg q3w) and pertuzumab (420 [840]mg q3w) with all P and C cycles. Primary end-point was pathological complete response (pCR, ypT0/is ypN0), secondary end-points included other pCR definitions, pCR in stratified subpopulations, tolerability and compliance. This trial is registered with ClinicalTrials.gov number NCT02125344. Results: 945/961 randomised patients started treatment. The median age was 48 years; 7.6% had cT3-4, 46% cN+, 66% G3, 40% HER2-positive, 43% TNBC. pCR rate with iddEPC was 48.3%, with PM(Cb) 48.0%, respectively (PM(Cb) versus iddEPC odds ratio 0.99; 95% confidence interval 0.77–1.28, P = 0.979) with no significant differences observed in TNBC, HER2-positive, luminal B-like subtypes. 16.4% with iddEPC and 34.1% with PM(Cb) discontinued treatment (P < 0.001), mainly due to adverse events; two patients on PM(Cb) died. Conclusions: In high-risk early BC there is no difference in pCR rates following neoadjuvant treatment with iddEPC or weekly PM(Cb), respectively. iddEPC is one of the effective dose-dense regimens feasible in daily practice.


FAU Authors / FAU Editors

Fasching, Peter PD Dr.
Professur für Translationale Frauenheilkunde und Geburtshilfe


External institutions with authors

Centrum für Hämatologie und Onkologie Bethanien
Charité - Universitätsmedizin Berlin
Deutsches Krebsforschungszentrum (DKFZ)
Diakoniekrankenhaus Henriettenstiftung
GBG Forschungs GmbH (German Breast Group)
HELIOS Kliniken
Kliniken Essen-Mitte
Klinikum Frankfurt Höchst
Luisenkrankenhaus Düsseldorf
Ortenau Klinikum
Praxis für Hämatologie und Onkologie Koblenz
Rotkreuzklinikum München
Sana Klinikum Offenbach
Universitätsklinikum Carl Gustav Carus Dresden
Universitätsklinikum Köln
Universitätsklinikum Ulm
Zentrum für Pathologie, Zytologie und Molekularpathologie Neuss


How to cite

APA:
Schneeweiss, A., Moebus, V., Tesch, H., Hanusch, C., Denkert, C., Luebbe, K.,... Loibl, S. (2019). Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial. European journal of cancer, 106, 181-192. https://dx.doi.org/10.1016/j.ejca.2018.10.015

MLA:
Schneeweiss, Andreas, et al. "Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial." European journal of cancer 106 (2019): 181-192.

BibTeX: 

Last updated on 2019-17-06 at 15:38